According to reports, the USFDA's Oncologic Advisory Committee voted that the risks from the drug, called Blenrep, outweighed ...

Investing.com -- GSK (LON: GSK) shares dropped more than 6% on Friday after a U.S. Food and Drug Administration advisory panel voted against the benefit-risk profile of Blenrep (belantamab ...

(Reuters) -European shares rose on Friday, on course for small weekly gains, as investors focussed on corporate earnings for ...

Reckitt Benckiser shares have lifted 2% or 110p to 5092p after the consumer goods giant secured a private equity buyer for ...

GSK was the standout laggard on the FTSE 100, sinking 6.2% after a US Food & Drug Administration advisory panel voted against approving its cancer drug Blenrep at the proposed dosage. Although the FDA ...

(Alliance News) - Stock prices in Europe opened higher early on Friday, with the FTSE 100 almost hitting a new record high, as a swathe of dealmaking was well-received in London. The FTSE 100 index ...